Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm PharmaceuticalsCAI:MIPH -1.34%50 Debt-to-EBITDA is 3.59 as of Dec. 2025, which is 7% above its 10-year median of 3.37. GuruFocus rates CAI:MIPH with a GF Score™ of 50/100 and a GF Value™ of E£366.79 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 687 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 71.18% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Minapharm Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
CAI:MIPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.54 Med: 3.37 Max: 7.88
Current: 3.37
During the past 5 years, the highest Debt-to-EBITDA Ratio of Minapharm Pharmaceuticals was 7.88. The lowest was 1.54. And the median was 3.37.
CAI:MIPH's Debt-to-EBITDA is ranked worse than 71.18% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs CAI:MIPH: 3.37
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Minapharm Pharmaceuticals Debt-to-EBITDA Related Terms
Minapharm Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Minapharm Pharmaceuticals (CAI:MIPH) has a Debt-to-EBITDA of 3.59 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Minapharm Pharmaceuticals. This is near median its historical median of 3.37. Over the past decade, Minapharm Pharmaceuticals' Debt-to-EBITDA has ranged from 1.54 to 7.88. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #489 out of 687 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Minapharm Pharmaceuticals' Debt-to-EBITDA too high?
Minapharm Pharmaceuticals' current Debt-to-EBITDA of 3.59 is near median its 10-year median of 3.37. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 7.88. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Minapharm Pharmaceuticals' value of 3.59 is 118.9% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #489 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #489 out of 687 companies for Debt-to-EBITDA. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Minapharm Pharmaceuticals' value of 3.59 is 118.9% above this benchmark. Historically, Minapharm Pharmaceuticals' own Debt-to-EBITDA has ranged from 1.54 to 7.88 over the past decade. While the company's 10-year median is 3.37 vs. the industry median of 1.64, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Debt-to-EBITDA of 3.59 is 118.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Minapharm Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Debt-to-EBITDA is 3.59, which is near median its own 10-year median of 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£366.79, compared to a current price of E£783.35 — trading 113.6% above its estimated fair value. The current Debt-to-EBITDA is 3.59, which is near median its 10-year median of 3.37 and 118.9% above the Drug Manufacturers industry median of 1.64. Minapharm Pharmaceuticals' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Debt-to-EBITDA is 3.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£783.35 is trading 113.6% above its estimated GF Value™ of E£366.79.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Debt-to-EBITDA: 3.59 (near median its 10-year median of 3.37)
GF Value™: E£366.79 vs. price of E£783.35 (113.6% above fair value)
Industry Position: 118.9% above the Drug Manufacturers median (#489 of 687)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
50GF Score
Get the complete analysis for CAI:MIPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
